-transparent.png){kind=logo}
Thirty-nine patients (28 men and 11 women, ages 43 to 83 years) with advanced head and neck epidermoid carcinoma (33 had relapsed from previous radiotherapy) were treated with a three-day bleomycin administration (30 by continuous intravenous infusion and nine by subcutaneous route) followed on the fifth day by intravenous administration of cyclophosphamide + methotrexate + 5-fluorouracil (Bleo-CMF). This drug schedule was based on the cell cycle synchrony principle. Twenty-one of 39 patients (54%) responded (seven complete, 14 partial remission) lasting from 4 to 20 months. The median duration of survival for complete remission, partial remission, and disease progression was 15, ten, and four months, respectively. The Bleo-CMF was well tolerated with minimal toxicity. The effectiveness of this regimen in previously irradiated patients compels us to pursue its application in a randomized study as an adjuvant for Stages III and IV head and neck cancer following maximum eradication of the local disease by surgery and/or radiotherapy.
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
February 1993,
The New England journal of medicine,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
February 1993,
The New England journal of medicine,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
February 1993,
The New England journal of medicine,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
April 1988,
Gan to kagaku ryoho. Cancer & chemotherapy,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
March 2009,
Expert review of anticancer therapy,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
August 1991,
Hematology/oncology clinics of North America,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
February 2003,
Clinical otolaryngology and allied sciences,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
October 2021,
British dental journal,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
September 1997,
International journal of radiation oncology, biology, physics,
E P Cortes, and
J Kalra, and
V C Amin, and
J Attie, and
L Eisenbud, and
R Khafif, and
D Wolk, and
I Aral, and
J Sciubba, and
N Akbiyik, and
K Heller
March 2006,
Expert review of anticancer therapy,
